JP2018066636A - Immunological measuring method, and measuring reagent - Google Patents
Immunological measuring method, and measuring reagent Download PDFInfo
- Publication number
- JP2018066636A JP2018066636A JP2016205039A JP2016205039A JP2018066636A JP 2018066636 A JP2018066636 A JP 2018066636A JP 2016205039 A JP2016205039 A JP 2016205039A JP 2016205039 A JP2016205039 A JP 2016205039A JP 2018066636 A JP2018066636 A JP 2018066636A
- Authority
- JP
- Japan
- Prior art keywords
- reagent
- sulfite
- measurement
- immunological
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 96
- 230000001900 immune effect Effects 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 46
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims abstract description 71
- 238000005259 measurement Methods 0.000 claims abstract description 65
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- 239000000427 antigen Substances 0.000 claims description 33
- 102000036639 antigens Human genes 0.000 claims description 33
- 108091007433 antigens Proteins 0.000 claims description 33
- 238000003018 immunoassay Methods 0.000 claims description 32
- 238000000691 measurement method Methods 0.000 claims description 30
- 239000004816 latex Substances 0.000 claims description 19
- 229920000126 latex Polymers 0.000 claims description 19
- 230000004520 agglutination Effects 0.000 claims description 12
- 230000002452 interceptive effect Effects 0.000 abstract description 16
- 230000000452 restraining effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 37
- 230000000694 effects Effects 0.000 description 15
- 230000003647 oxidation Effects 0.000 description 11
- 238000007254 oxidation reaction Methods 0.000 description 11
- 230000001629 suppression Effects 0.000 description 11
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000004793 Polystyrene Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 235000010265 sodium sulphite Nutrition 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000011923 Thyrotropin Human genes 0.000 description 4
- 108010061174 Thyrotropin Proteins 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010019799 Hepatitis viral Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 201000001862 viral hepatitis Diseases 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- 102000004576 Placental Lactogen Human genes 0.000 description 2
- 108010003044 Placental Lactogen Proteins 0.000 description 2
- 239000000381 Placental Lactogen Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 241000473945 Theria <moth genus> Species 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- PQUCIEFHOVEZAU-UHFFFAOYSA-N Diammonium sulfite Chemical compound [NH4+].[NH4+].[O-]S([O-])=O PQUCIEFHOVEZAU-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- ZETCGWYACBNPIH-UHFFFAOYSA-N azane;sulfurous acid Chemical compound N.OS(O)=O ZETCGWYACBNPIH-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- GBAOBIBJACZTNA-UHFFFAOYSA-L calcium sulfite Chemical compound [Ca+2].[O-]S([O-])=O GBAOBIBJACZTNA-UHFFFAOYSA-L 0.000 description 1
- 235000010261 calcium sulphite Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- VYKVQJFOZDGJLN-UHFFFAOYSA-M sodium hydrogen sulfite sulfurous acid Chemical compound [Na+].OS(O)=O.OS([O-])=O VYKVQJFOZDGJLN-UHFFFAOYSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
本発明は、被測定物質の免疫学的方法での測定において、異好性抗体やリウマトイド因子等の干渉物質(以下、干渉物質)による干渉作用を抑制し、抗原または抗体濃度を正確に測定することができる免疫学的測定方法、および免疫学的測定試薬に関するものである。 In the measurement of a substance to be measured by an immunological method, the present invention suppresses the interference action by an interfering substance (hereinafter referred to as an interfering substance) such as a heterophilic antibody and a rheumatoid factor, and accurately measures an antigen or antibody concentration. The present invention relates to an immunological measurement method and an immunological measurement reagent.
抗原と抗体との間の抗原抗体反応を利用した免疫学的測定法は、生体中の蛋白質等の免疫学的活性物質を簡便、迅速に測定できることから、近年、各種疾患の診断に広く利用されている。このような免疫学的測定法としては、放射免疫測定法(RIA)、酵素免疫測定法(EIA)、蛍光免疫測定法(FIA)、免疫比濁法(TIA)、ラテックス凝集法(LA)、イムノクロマトグラフィー法等の種々の方法が実用化されている。 In recent years, immunoassays using antigen-antibody reactions between antigens and antibodies have been widely used in the diagnosis of various diseases because immunologically active substances such as proteins in living organisms can be measured easily and rapidly. ing. Such immunological assays include radioimmunoassay (RIA), enzyme immunoassay (EIA), fluorescence immunoassay (FIA), immunoturbidimetric method (TIA), latex agglutination (LA), Various methods such as immunochromatography have been put into practical use.
しかしながら、免疫学測定法の測定対象となる検体の中には、抗原抗体反応に対して干渉する干渉物質等が含まれている場合がある。これら抗原抗体反応に干渉物質が含まれると、測定結果に影響するため正確な測定ができなくなり、特に臨床検査の分野では、正確な診断ができなくなるため、これまで、干渉物質の影響を軽減、あるいは抑制する方法が提案されている。 However, there are cases in which an analyte that interferes with an antigen-antibody reaction is included in a sample to be measured by an immunological measurement method. If interference substances are included in these antigen-antibody reactions, the measurement results will be affected and accurate measurement will not be possible. Especially in the field of clinical examinations, accurate diagnosis will not be possible. Alternatively, a suppression method has been proposed.
例えば、リウマトイド因子の混在による干渉作用の問題を解決するため、検体を予めヒトリウマトイド因子の結合部位に結合する動物由来抗体で前処理して、リウマトイド因子による干渉作用を低減させる免疫学的測定法(特許文献1)や、反応液のpHを4.0から6.0に保つことにより、リウマトイド因子の干渉作用を抑制する免疫学的測定法(特許文献2)等が提案されている。 For example, in order to solve the problem of interference caused by the mixing of rheumatoid factor, an immunological measurement method that reduces the interference caused by rheumatoid factor by pretreating the specimen with an animal-derived antibody that binds to the binding site of human rheumatoid factor in advance. (Patent Document 1) and an immunological measurement method (Patent Document 2) that suppresses the interference action of a rheumatoid factor by maintaining the pH of the reaction solution at 4.0 to 6.0 have been proposed.
また、干渉物質による干渉作用を軽減あるいは抑制するため、免疫学的測定に使用する抗体のFc部分を酵素反応で除去したF(ab’)2を使用する方法が提案されている(特許文献3)。しかしながら、この免疫学的測定法では、抗原を測定する場合にしか利用できず、しかもF(ab’)2作製のための酵素反応や精製等の煩雑な工程が必要であり、コストアップや製造ロット間差という問題があった。 Also, a method of using F (ab ′) 2 obtained by removing the Fc portion of an antibody used for immunological measurement by an enzymatic reaction has been proposed in order to reduce or suppress the interference action caused by the interfering substance (Patent Document 3). ). However, this immunological measurement method can be used only when measuring an antigen, and requires complicated steps such as an enzyme reaction and purification for preparing F (ab ′) 2 , resulting in an increase in cost and production. There was a problem of difference between lots.
さらに、重合化または凝集した抗体分子を利用する、異好性抗体による干渉作用を抑制する方法も提案されている(特許文献4)が、異好性抗体による干渉作用を完全に抑制するためには大量の重合化または凝集した抗体分子が必要であり、コストが高くなるという問題がある。 Furthermore, a method for suppressing the interference action caused by heterophilic antibodies using polymerized or aggregated antibody molecules has also been proposed (Patent Document 4). In order to completely suppress the interference action caused by heterophilic antibodies, Requires a large amount of polymerized or aggregated antibody molecules, which increases the cost.
これらの文献に記載された、干渉物質による干渉作用を抑制する方法では、確かに干渉物質による影響は改善されるものの、測定すべき試料中に干渉物質が高濃度で含まれる場合には、その干渉作用を抑制する効果は不十分であった。 Although the methods described in these documents for suppressing the interference effect of the interference substance certainly improve the influence of the interference substance, if the sample to be measured contains the interference substance at a high concentration, The effect of suppressing the interference action was insufficient.
測定すべき試料中に干渉物質が高濃度で含まれる場合であっても、干渉物質による干渉作用を抑制することができる、亜硫酸塩を利用するする方法(特許文献5)が提案されている。亜硫酸塩は非常に安価であり、高濃度の干渉物質の影響を十分に抑制できるような濃度で使用してもコストを上げることがなく、また、抗原抗体反応に影響を与えにくいという利点がある。 A method using sulfite has been proposed (Patent Document 5) that can suppress the interference action of an interference substance even if the sample to be measured contains an interference substance at a high concentration. Sulfite is very inexpensive and has the advantage that it does not increase costs even when used at a concentration that can sufficiently suppress the effects of high concentrations of interfering substances, and it does not easily affect antigen-antibody reactions. .
しかしながら、亜硫酸塩は測定試薬中の溶存酸素または空気中の酸素により徐々に硫酸塩に酸化されるため、干渉物質による干渉作用の抑制効果が経時的に低下する。すなわち、自動分析装置等で使用するために、開封状態で試薬庫等に保存することにより経時的に亜硫酸塩濃度が減少し、干渉物質の影響を十分に抑制できなくなるという問題があった。また、干渉物質が高濃度の場合は、その干渉作用を十分に抑制できないこともあるという問題もあった。 However, since sulfite is gradually oxidized to sulfate by dissolved oxygen in the measurement reagent or oxygen in the air, the effect of suppressing the interference action by the interference substance decreases with time. That is, since it is used in an automatic analyzer or the like and stored in a reagent store or the like in an opened state, the sulfite concentration decreases with time, and the influence of interference substances cannot be sufficiently suppressed. In addition, when the interference substance has a high concentration, there is a problem that the interference action may not be sufficiently suppressed.
従って本発明は、上記の現状に着目してなされたものであって、測定する試料中に干渉物質が高濃度に含まれる場合であっても、これらによる干渉作用を長期間にわたって抑制することができる安定性の高い疫学的測定方法およびこれを用いた測定試薬を提供することを目的とする。 Therefore, the present invention has been made paying attention to the above-mentioned present situation, and even when a sample to be measured contains an interfering substance at a high concentration, the interference action due to these can be suppressed over a long period. An object of the present invention is to provide a highly stable epidemiological measurement method and a measurement reagent using the same.
本発明者は、上記課題を解決すべく鋭意研究した結果、亜硫酸塩を含む測定試薬のpHを7.0以下にすることにより、長期間にわたり高い干渉物質に対する抑制効果がえられることを見出し、本発明を完成した。 As a result of diligent research to solve the above problems, the present inventor has found that by suppressing the pH of a measurement reagent containing sulfite to 7.0 or less, a high inhibitory effect on interfering substances can be obtained over a long period of time. The present invention has been completed.
すなわち、本発明は以下の構成よりなる。
(1)免疫学的測定試薬を用いて、亜硫酸塩の存在下で、抗原抗体反応を行う免疫学的測定法において、亜硫酸を含有する免疫学的測定試薬のpHが7.0以下であることを特徴とする前記免疫学的測定方法。
(2)前記亜硫酸塩を含有する免疫学的測定試薬のpHが5.6から7.0の範囲である(1)に記載の免疫学的測定方法。
(3)前記亜硫酸塩が50mM以上である(1)または(2)に記載の免疫学低測定方法。
(4)前記亜硫酸塩が50mMから600mMである(1)から(3)のいずれか1項に記載の免疫学的測定方法。
(5) 前記免疫学的測定試薬を含む第1試薬と、測定対象物と反応する抗体または抗原、もしくは測定対象物と反応する抗体または抗原を担持した担体を含む第2試薬とを混合する工程を含む、測定対象物を定量または定性測定する(1)から(4)のいずれか1項に記載の免疫学的測定方法。
(6)免疫学的測定方法が、ラテックス凝集法である(1)から(5)のいずれか1項に記載の免疫学的測定方法。
That is, the present invention has the following configuration.
(1) In an immunoassay method in which an antigen-antibody reaction is performed in the presence of sulfite using an immunoassay reagent, the pH of the immunoassay reagent containing sulfite is 7.0 or less The immunological measurement method described above.
(2) The immunological measurement method according to (1), wherein the pH of the immunological measurement reagent containing sulfite is in the range of 5.6 to 7.0.
(3) The immunological low measurement method according to (1) or (2), wherein the sulfite is 50 mM or more.
(4) The immunological measurement method according to any one of (1) to (3), wherein the sulfite is 50 mM to 600 mM.
(5) A step of mixing the first reagent containing the immunological measurement reagent with the second reagent containing the antibody or antigen that reacts with the measurement object or the antibody or antigen that reacts with the measurement object. The immunological measurement method according to any one of (1) to (4), wherein the measurement object is quantitatively or qualitatively measured.
(6) The immunological measurement method according to any one of (1) to (5), wherein the immunological measurement method is a latex agglutination method.
(7)亜硫酸塩の存在下で、抗原抗体反応を行う免疫学的測定試薬であって、亜硫酸塩を含有する免疫学的測定試薬のpHが7.0以下であることを特徴とする前記免疫学的測定試薬。
(8)前記亜硫酸塩を含有する試薬のpHが5.6から7.0の範囲である(7)に記載の免疫学的測定試薬。
(9)前記亜硫酸塩が50mM以上である(7)または(8)記載の免疫学低測定試薬。
(10)前記亜硫酸塩が50mMから600mMである(7)から(9)のいずれか1項に記載の免疫学的測定試薬。
(11)免疫学的測定方法が、ラテックス凝集法である(7)から(10)のいずれか1項に記載の免疫学的測定試薬。
(12)(7)から(11)のいずれか1項に記載の免疫学的測定試薬と、測定対象物と反応する抗体または抗原、もしくは測定対象物と反応する抗体または抗原を担持した担体とを含む免疫学的測定試薬キット。
(7) An immunoassay reagent for performing an antigen-antibody reaction in the presence of sulfite, wherein the immunoassay reagent containing sulfite has a pH of 7.0 or less. Measurement reagent.
(8) The immunoassay reagent according to (7), wherein the pH of the reagent containing sulfite is in the range of 5.6 to 7.0.
(9) The immunological low measurement reagent according to (7) or (8), wherein the sulfite is 50 mM or more.
(10) The immunoassay reagent according to any one of (7) to (9), wherein the sulfite is 50 mM to 600 mM.
(11) The immunological measurement reagent according to any one of (7) to (10), wherein the immunological measurement method is a latex agglutination method.
(12) The immunological measurement reagent according to any one of (7) to (11), an antibody or antigen that reacts with the measurement object, or a carrier that carries an antibody or antigen that reacts with the measurement object; An immunological measurement reagent kit.
本発明は、亜硫酸塩を含む免疫学的測定試薬のpHを7.0以下にすることにより、測定対象である試料中に、抗原抗体反応に対する干渉物質が高濃度で含まれる場合においても、干渉物質の影響を受けることなく免疫学的測定を行うことができる、安定性にすぐれた免疫学的測定試薬を提供する。 In the present invention, the pH of an immunological measurement reagent containing sulfite is adjusted to 7.0 or less, so that even when a sample to be measured contains an interfering substance for antigen-antibody reaction at a high concentration, the interference can be prevented. Provided is an immunoassay reagent having excellent stability, which can perform immunoassay without being affected by a substance.
そして、この免疫学的測定により得られる結果についても、信頼性の高いものとなることが期待される。 The results obtained by this immunological measurement are also expected to be highly reliable.
驚くべきことに、亜硫酸塩を含有する試薬のpHを、特許文献5実施例に記載されているpH7.4から、わずかに低下させるだけで、亜硫酸塩による干渉物質の抑制効果だけでなく、亜硫酸塩を含有する、免疫学的測定試薬や前処理試薬の安定性も向上させることができる。 Surprisingly, by reducing the pH of the reagent containing sulfite slightly from the pH 7.4 described in Example of Patent Document 5, not only the inhibitory effect of interfering substances by sulfite but also sulfite. The stability of the immunological measurement reagent or pretreatment reagent containing a salt can also be improved.
以下、本発明の好適な実施形態について説明する。
本発明の一実施形態は、亜硫酸塩の存在下で、免疫学的測定試薬を用いて抗原抗体反応を行う免疫学的測定法において、亜硫酸塩を含有する免疫学的測定試薬のpHを7.0以下にした免疫学的測定方法である 。
Hereinafter, preferred embodiments of the present invention will be described.
In one embodiment of the present invention, in an immunoassay in which an antigen-antibody reaction is performed using an immunoassay reagent in the presence of sulfite, the pH of the immunoassay reagent containing sulfite is set to 7. This is an immunological measurement method with 0 or less.
本発明において、「免疫学的測定法」とは、測定対象である測定対象物と特異的に結合する物質(例えば、抗体または抗原)を用いて、測定対象物の存在の有無の判定(検出)や、測定対象物が存在する場合にはその存在量の測定(定量)を行う方法であり、例えば、サンドイッチ法、競合法の原理に基づくRIA法やELISA法、免疫凝集反応法に基づく免疫比濁法(TIA法)やラテックス凝集法(LIA法)等が挙げられる。 In the present invention, the “immunological measurement method” refers to the determination (detection) of the presence or absence of a measurement target using a substance (for example, an antibody or an antigen) that specifically binds to the measurement target. ) And the measurement (quantification) of the abundance when the measurement object exists, for example, the RIA method or ELISA method based on the principle of the sandwich method, the competitive method, or the immunity based on the immunoagglutination method. Examples thereof include a turbidimetric method (TIA method) and a latex agglutination method (LIA method).
本発明の「免疫学的測定試薬」とは抗原抗体反応を行う免疫学的測定方法に用いる試薬であり、亜硫酸塩を含む。さらに、本発明の免疫学的測定方法は測定対象物質を含む測定試料の前処理試薬として用いることができる。 The “immunological measurement reagent” of the present invention is a reagent used in an immunological measurement method for performing an antigen-antibody reaction, and includes sulfite. Furthermore, the immunological measurement method of the present invention can be used as a pretreatment reagent for a measurement sample containing a measurement target substance.
本発明の「前処理試薬」とは、免疫学的測定方法を用いて測定対象物質を含む測定試料を測定する前に、測定試料を処理するために用いる試薬であり、亜硫酸塩を含む。前処理試薬によって処理した測定試料は、そのまま公知の免疫学的測定方法の測定試料とすることができる。 The “pretreatment reagent” of the present invention is a reagent used for treating a measurement sample before measuring the measurement sample containing the substance to be measured using an immunological measurement method, and includes sulfite. The measurement sample treated with the pretreatment reagent can be used as it is as a measurement sample of a known immunological measurement method.
本発明に使用する亜硫酸塩は公知のものから適宜選択することができる。亜硫酸塩としては、例えば、亜硫酸ナトリウム、亜硫酸カリウム、亜硫酸カルシウム、亜硫酸アンモニウム、亜硫酸水素ナトリウム、亜硫酸水素アンモニウム等が挙げられる。 The sulfite used in the present invention can be appropriately selected from known ones. Examples of the sulfite include sodium sulfite, potassium sulfite, calcium sulfite, ammonium sulfite, sodium hydrogen sulfite, and ammonium hydrogen sulfite.
本発明において、亜硫酸塩が免疫学的測定試薬または前処理試薬に含まれる場合、免疫学的測定試薬または前処理試薬中の亜硫酸塩濃度は、50mM以上、好ましくは50mMから600mM、より好ましくは100mMから600mM、さらに好ましくは250mMから500mMである。硫酸塩の濃度が50mM未満になると免疫反応に影響を与える干渉物質の影響を十分に抑制しにくく、600mMを超えても干渉物質の影響を効果的に抑制できなくなり、また、溶液の粘度上昇により測定に悪影響を与えうる。 In the present invention, when sulfite is contained in the immunological measurement reagent or pretreatment reagent, the sulfite concentration in the immunological measurement reagent or pretreatment reagent is 50 mM or more, preferably 50 mM to 600 mM, more preferably 100 mM. To 600 mM, more preferably 250 mM to 500 mM. When the sulfate concentration is less than 50 mM, it is difficult to sufficiently suppress the influence of interfering substances that affect the immune reaction, and even when the concentration exceeds 600 mM, the influence of interfering substances cannot be effectively suppressed, and the increase in the viscosity of the solution. May adversely affect measurement.
本発明の亜硫酸塩を含有する免疫学的測定試薬または前処理試薬のpHは、7.0以下が好ましく、pH5.6からpH7.0がより好ましい。pH5.6を下回ると蛋白質等の変性が起こりやすく正確な測定に影響を与えることとなり、pH7.0を超えると干渉物質の影響の抑制効果が経時的に低下しやすくなる。 The pH of the immunoassay or pretreatment reagent containing the sulfite of the present invention is preferably 7.0 or less, and more preferably from pH 5.6 to pH 7.0. If the pH is below 5.6, denaturation of proteins and the like is likely to occur, and accurate measurement is affected. If the pH is above 7.0, the effect of suppressing the influence of interfering substances tends to decrease over time.
本発明においては、必要に応じて公知の蛋白質保護剤を加えて測定対象物質の安定性を高めることができる。このような蛋白質保護剤としては、アルブミンやゼラチン等の蛋白質や合成ポリマー素材、界面活性剤等を挙げることができる。 In the present invention, if necessary, a known protein protective agent can be added to increase the stability of the substance to be measured. Examples of such protein protecting agents include proteins such as albumin and gelatin, synthetic polymer materials, surfactants, and the like.
本発明の亜硫酸塩を含有する免疫学的測定試薬または前処理試薬によって干渉物質の影響を抑制した試料は、そのまま公知の免疫学的測定方法により測定することができる。免疫学的測定方法としては、例えば、サンドイッチ法、競合法の原理に基づくRIA法やELISA法、免疫凝集反応法に基づく免疫比濁法(TIA法)やラテックス凝集法(LIA法)等が挙げられる。 The sample in which the influence of the interfering substance is suppressed by the immunological measurement reagent or the pretreatment reagent containing the sulfite of the present invention can be directly measured by a known immunological measurement method. Examples of immunological measurement methods include the sandwich method, the RIA method and ELISA method based on the principle of the competitive method, the immunoturbidimetric method (TIA method) and the latex agglutination method (LIA method) based on the immunoagglutination method. It is done.
これらの免疫学的測定方法の中でも、特に測定試料中の被測定物質である抗原(または抗体)と測定試薬中の抗体(または抗原)とを反応させ、その結果生じる免疫凝集物を検出することを測定原理とする、免疫比濁法やラテックス凝集法が好ましい。 Among these immunological measurement methods, in particular, the antigen (or antibody) that is the substance to be measured in the measurement sample is reacted with the antibody (or antigen) in the measurement reagent, and the resulting immune aggregate is detected. The immunoturbidimetric method and latex agglutination method, which employs the measurement principle, are preferred.
本発明の免疫学的測定試薬は、免疫比濁法やラテックス凝集法に用いることができ、緩衝液を含む第1試薬、および緩衝液に抗体または抗原、もしくは抗体または抗原を担持させた担体(好ましくはラテックス粒子)を含有させた第2試薬の2つの試薬から構成することができる。 The immunological measurement reagent of the present invention can be used in an immunoturbidimetric method or a latex agglutination method, and includes a first reagent containing a buffer, and an antibody or antigen, or a carrier carrying an antibody or an antigen in the buffer ( Preferably, it can be composed of two reagents of the second reagent containing latex particles.
免疫比濁法やラテックス凝集法による免疫学的測定試薬に用いることができる緩衝液としては、pHを一定に保てるものであれば特に限定されず、公知のものから適宜選択することができる。例えば、りん酸緩衝液、トリス緩衝液、グッド緩衝液等が挙げられる。 The buffer solution that can be used for the immunoassay reagent by the immunoturbidimetric method or the latex agglutination method is not particularly limited as long as the pH can be kept constant, and can be appropriately selected from known ones. For example, phosphate buffer, Tris buffer, Good buffer, etc. are mentioned.
本発明の亜硫酸塩を含有する免疫学的測定試薬を、前記2つの試薬から構成される免疫比濁法やラテックス凝集法等の免疫学的測定試薬の第1試薬とすることもできる。すなわち、本発明の干渉物質の影響の抑制方法を用いた第1試薬に、測定試料を混合した後に、この混合液に抗体(または抗原)、あるいは抗体(または抗原)を担持させたラテックス粒子等を含む第2試薬を混和して測定してもよい。 The immunoassay reagent containing the sulfite of the present invention can also be used as a first reagent of an immunoassay reagent such as an immunoturbidimetric method or a latex agglutination method composed of the two reagents. That is, after mixing the measurement sample with the first reagent using the method for suppressing the influence of the interfering substance of the present invention, an antibody (or antigen) or latex particles carrying the antibody (or antigen) in the mixed solution, etc. Measurement may be carried out by mixing a second reagent containing
また、本発明の干渉物質の影響の抑制方法を用いた前処理試薬と測定試料を混合した後、この混合液を、ELISA法やラテックス凝集法等の免疫学的測定方法の測定試料として測定してもよい。 In addition, after mixing the pretreatment reagent and the measurement sample using the method for suppressing the influence of the interference substance of the present invention, this mixed solution is measured as a measurement sample for an immunological measurement method such as an ELISA method or a latex agglutination method. May be.
本発明においては、担体に担持させる抗体または抗原としては、特に限定されず、公知のものから適宜選択することができる。担体に担持させる抗体または抗原としては、例えば、C反応性蛋白(CRP)、トランスフェリン等の血漿蛋白質に対する抗体、甲状腺刺激ホルモン(TSH)、サイロキシン、インスリン、ヒト胎盤性ラクトーゲン等のホルモンに対する抗体、癌胎児性抗原(CEA)、β2−マイクログロブリン、α―フェトプロテイン(AFP)等の腫瘍関連物質に対する抗体、HBs抗原、HBe抗原等のウイルス性肝炎の抗原に対する抗体およびHBs抗体、HBe抗体等のウイルス性肝炎の抗体に対する抗原、ヘルペス、麻疹、風疹等のウイルス、各種生体成分に対する抗体または抗原、フェノバルビタール、アセトアミノフェン、サイクロスポリン等の各種薬剤に対する抗体等が挙げられる。 In the present invention, the antibody or antigen carried on the carrier is not particularly limited and can be appropriately selected from known ones. Examples of antibodies or antigens carried on a carrier include antibodies to plasma proteins such as C-reactive protein (CRP) and transferrin, antibodies to hormones such as thyroid stimulating hormone (TSH), thyroxine, insulin, and human placental lactogen, cancer Antibodies against tumor-related substances such as fetal antigen (CEA), β2-microglobulin, α-fetoprotein (AFP), antibodies against viral hepatitis antigens such as HBs antigen and HBe antigen, and viral properties such as HBs antibody and HBe antibody Examples include antigens against hepatitis antibodies, viruses such as herpes, measles and rubella, antibodies or antigens against various biological components, antibodies against various drugs such as phenobarbital, acetaminophen, and cyclosporine.
本発明において、抗体または抗原を担持させる担体としては、特に制限されず、公知のものから適宜選択することができる。抗体または抗原を担持させる担体としては、ポリスチレンプレート、ポリスチレンビーズ、ラテックス粒子、金属コロイド粒子、シリカコロイド粒子等が挙げられる。 In the present invention, the carrier for supporting the antibody or antigen is not particularly limited and can be appropriately selected from known ones. Examples of the carrier for supporting the antibody or antigen include polystyrene plates, polystyrene beads, latex particles, metal colloid particles, silica colloid particles, and the like.
本発明で使用できる上記抗体としては、由来する動物種は特に限定されず、例えば、ウサギ、ヤギ、マウス、ラット、ウマ、ヒツジ等の動物に由来する抗体が挙げられ、測定対象物を免疫した動物の血清から得られるポリクローナル、測定対象物を免疫した動物の脾臓をミエローマ細胞と細胞融合して得られるモノクローナル抗体のいずれを用いてもよい。 The above-mentioned antibodies that can be used in the present invention are not particularly limited, and examples thereof include antibodies derived from animals such as rabbits, goats, mice, rats, horses, sheep, etc. Either a polyclonal antibody obtained from animal serum or a monoclonal antibody obtained by cell fusion of the spleen of an animal immunized with a measurement object with myeloma cells may be used.
本発明において、測定試料は特に限定されず、例えば、血液、血清、血漿、尿、リンパ液、 刺液、髄液、汗、唾液、胃液、肺洗浄液、糞便等が挙げられる。これらのうち、血清、血漿が特に好ましい。 In the present invention, the measurement sample is not particularly limited, and examples thereof include blood, serum, plasma, urine, lymph fluid, stab fluid, spinal fluid, sweat, saliva, gastric fluid, lung lavage fluid, feces and the like. Of these, serum and plasma are particularly preferred.
また、本発明において、測定対象物質についても特に限定されず、例えば、C反応性蛋白(CRP)、トランスフェリン等の血漿蛋白質、甲状腺刺激ホルモン(TSH)、サイロキシン、インスリン、ヒト胎盤性ラクトーゲン等のホルモン、癌胎児性抗原(CEA)、β2−マイクログロブリン、α―フェトプロテイン(AFP)等の腫瘍関連物質、HBs抗原、HBe抗原等のウイルス性肝炎の抗原およびHBs抗体、HBe抗体等のウイルス性肝炎の抗体、ヘルペス、麻疹、風疹等のウイルス、各種生体成分に対する抗体または抗原、フェノバルビタール、アセトアミノフェン、サイクロスポリン等の各種薬剤等が挙げられる。 In the present invention, the substance to be measured is not particularly limited. For example, plasma proteins such as C-reactive protein (CRP) and transferrin, thyroid stimulating hormone (TSH), thyroxine, insulin, human placental lactogen and other hormones Tumor-related substances such as carcinoembryonic antigen (CEA), β2-microglobulin, α-fetoprotein (AFP), viral hepatitis antigens such as HBs antigen and HBe antigen, and viral hepatitis such as HBs antibody and HBe antibody Examples include antibodies, viruses such as herpes, measles and rubella, antibodies or antigens against various biological components, various drugs such as phenobarbital, acetaminophen, and cyclosporine.
以下、実施例に基づいて本発明を具体的に説明するが、本発明はこれらの実施例に限定されるものではない。 EXAMPLES Hereinafter, although this invention is demonstrated concretely based on an Example, this invention is not limited to these Examples.
実施例1 干渉反応抑制効果に対する亜硫酸塩濃度の影響
硫酸ナトリウム添加による干渉反応の抑制に対する亜硫酸塩濃度の影響を評価した。また、亜硫酸塩の酸化を促進する条件(試薬容器に半分充填し4℃で3週間振とう)で保存して安定性を評価した。
Example 1 Effect of Sulphite Concentration on Interference Reaction Suppression Effect The effect of sulfite concentration on the suppression of interference reaction by adding sodium sulfate was evaluated. Further, the stability was evaluated by storage under conditions that promote the oxidation of sulfite (half-filled reagent container and shaken at 4 ° C. for 3 weeks).
(1)試薬
第1試薬:150mM NaCl、0.1% NaN3、0.1% ポリオキシエチレンポリオキシプロピレンセチルエーテル、0mM、50mM、100mM、250mM、350mM、500mMまたは600mMの亜硫酸ナトリウムを含む50mM HEPES緩衝液(pH7.4)を調製した。また、調製した第1試薬を試薬容器に半分充填し、4℃で3週間振とうして、亜硫酸塩の空気中の酸素による酸化を促進させた。
第2試薬:抗KL−6抗体担持ポリスチレンラテックス液、400mM アルギニン塩酸塩、0.1% NaN3を含む50mM HEPES緩衝液(pH7.4)を調製した。
(1) Reagent
First reagent: 50 mM HEPES buffer containing 150 mM NaCl, 0.1% NaN 3 , 0.1% polyoxyethylene polyoxypropylene cetyl ether, 0 mM, 50 mM, 100 mM, 250 mM, 350 mM, 500 mM, or 600 mM sodium sulfite ( pH 7.4) was prepared. Further, half of the prepared first reagent was filled in a reagent container and shaken at 4 ° C. for 3 weeks to promote oxidation of sulfite by oxygen in the air.
Second reagent: A 50 mM HEPES buffer (pH 7.4) containing an anti-KL-6 antibody-supported polystyrene latex solution, 400 mM arginine hydrochloride, and 0.1% NaN 3 was prepared.
上記の抗KL−6担持ラテックス液は、公知の方法により調製した。すなわち、抗KL−6抗体とポリスチレンラテックスを混合して、ポリスチレンラテックス表面に抗KL−6抗体を担持することにより調製した。 Said anti-KL-6 carrying | support latex liquid was prepared by the well-known method. That is, it was prepared by mixing an anti-KL-6 antibody and polystyrene latex and supporting the anti-KL-6 antibody on the polystyrene latex surface.
(2)測定試料
プール血清に干渉チェックRFプラス(シスメックス株式会社)をリウマトイド因子濃度が、0、100、200、300、400、500、または1000IU/mLとなるように添加してRF試料を調製した。
(2) RF sample is prepared by adding interference check RF plus (Sysmex Corporation) to the measurement sample pool serum so that the rheumatoid factor concentration is 0, 100, 200, 300, 400, 500, or 1000 IU / mL. did.
(3)評価方法
前記RF試料2.0μLに第1試薬120μLを混合し37℃で5分間インキュベーションした後、この混合液に第2試薬を40μL混合し37℃で反応させ、第2試薬混合後約5分間の660nmの吸光度変化を測定した。なお、一連の測定は日立7180形自動分析装置(株式会社日立ハイテクノロジーズ)を用いて行った。
KL−6の濃度を定量するため、KL−6の標準物質を測定して得られた検量線から、血清検体中のKL−6濃度を算出した。調製直後の結果を表1に、亜硫酸塩の酸化を促進させた場合の結果を表2に示す。
(3) Evaluation method After 120 μL of the first reagent is mixed with 2.0 μL of the RF sample and incubated at 37 ° C. for 5 minutes, 40 μL of the second reagent is mixed with this mixed solution and reacted at 37 ° C. After mixing the second reagent The change in absorbance at 660 nm for about 5 minutes was measured. A series of measurements was performed using a Hitachi 7180 automatic analyzer (Hitachi High-Technologies Corporation).
In order to quantify the concentration of KL-6, the concentration of KL-6 in the serum sample was calculated from a calibration curve obtained by measuring the standard substance of KL-6. The results immediately after the preparation are shown in Table 1, and the results when the oxidation of sulfite is promoted are shown in Table 2.
表1より、亜硫酸塩濃度50mM以上でRFによる干渉反応の抑制効果がみられ、亜硫酸塩濃度50mMにおいても、RFによる干渉反応を亜硫酸塩無添加時(0mM)の約1/2に抑制できることがわかった。また、干渉反応の抑制効果は、亜硫酸塩濃度に依存して向上し亜硫酸塩濃度250mMから500mMで抑制効果は最大となり、亜硫酸塩濃度600mMでは低下することがわかった。亜硫酸塩濃度は50mM以上が好ましく、50mMから600mMがより好ましく、100mMから600mMがさらに好ましく、250mMから500mMが最も好ましい。 From Table 1, the effect of suppressing interference reaction by RF is seen at a sulfite concentration of 50 mM or more, and even at a sulfite concentration of 50 mM, the interference reaction by RF can be suppressed to about ½ of that when no sulfite is added (0 mM). all right. In addition, it was found that the suppression effect of the interference reaction was improved depending on the sulfite concentration, the suppression effect was maximized at a sulfite concentration of 250 mM to 500 mM, and decreased at a sulfite concentration of 600 mM. The sulfite concentration is preferably 50 mM or more, more preferably 50 mM to 600 mM, still more preferably 100 mM to 600 mM, and most preferably 250 mM to 500 mM.
また、表1と表2より、亜硫酸塩濃度が50mMの場合には、亜硫酸塩の酸化により干渉反応の抑制効果が低下している。干渉反応の抑制効果に対する亜硫酸塩の酸化の影響は、亜硫酸塩濃度に依存して軽減され、亜硫酸塩濃度250mMから500mMで最も影響が小さくなり安定性が向上したが、亜硫酸濃度が600mMの場合には、亜硫酸塩の酸化により干渉反応の抑制効果が低下することがわかった。 Also, from Tables 1 and 2, when the sulfite concentration is 50 mM, the interference reaction suppression effect is reduced due to oxidation of sulfite. The effect of sulfite oxidation on the inhibition effect of interference reaction is reduced depending on the sulfite concentration, and the effect is minimized and the stability is improved at a sulfite concentration of 250 mM to 500 mM. However, when the sulfite concentration is 600 mM, It was found that the effect of suppressing interference reaction is reduced by oxidation of sulfite.
実施例2 亜硫酸塩の干渉反応の抑制に対するpHの影響
亜硫酸ナトリウムを250mMとして、干渉物質の干渉反応の抑制に対するpHの影響を評価した。
Example 2 Influence of pH on inhibition of interference reaction of sulfite Sodium sulfite was set to 250 mM, and the influence of pH on inhibition of interference reaction of an interference substance was evaluated.
(1)試薬
第1試薬:150mM NaCl、0.1% NaN3、0.1% ポリオキシエチレンポリオキシプロピレンセチルエーテル、250mM 亜硫酸ナトリウムを含む50mM PIPES緩衝液(pH6.4または6.8)または50mM HEPES緩衝液(pH7.4または7.8)を調製した。
第2試薬:実施例1と同様である。
(2)測定試料
プール血清に干渉チェックRFプラス(シスメックス株式会社)をリウマトイド因子濃度が、0、100、200、300、400、または500IU/mLとなるように添加してRF試料を調製したRF試料に加え、正常検体(異好性抗体およびRF陰性のヒト血清試料)および異常検体(異好性抗体およびRF陽性のヒト血清試料)を試料とした。
(3)評価方法
実施例1と同様に試料を測定した。RF試料の結果を表3に、ヒト血清試料の結果を表4に示す。
(1) Reagent
First reagent: 50 mM PIPES buffer (pH 6.4 or 6.8) or 50 mM HEPES buffer containing 150 mM NaCl, 0.1% NaN 3 , 0.1% polyoxyethylene polyoxypropylene cetyl ether, 250 mM sodium sulfite (PH 7.4 or 7.8) was prepared.
Second reagent: The same as in Example 1.
(2) Measurement sample RF prepared by adding interference check RF plus (Sysmex Corporation) to the pooled serum so that the rheumatoid factor concentration is 0, 100, 200, 300, 400, or 500 IU / mL. In addition to the samples, normal samples (heterophilic antibodies and RF negative human serum samples) and abnormal samples (heterophilic antibodies and RF positive human serum samples) were used as samples.
(3) Evaluation method A sample was measured in the same manner as in Example 1. Table 3 shows the results of the RF sample, and Table 4 shows the results of the human serum sample.
表3より明らかなように、亜硫酸塩によるRFの干渉反応の抑制効果は、pH7.8以上では高pHほど顕著に低下し、測定値の正誤差が拡大する。しかし、pH7.4以下での亜硫酸塩によるRFの干渉反応の抑制効果には大きな差異は見られない。 As is apparent from Table 3, the effect of suppressing the RF interference reaction by sulfite is significantly reduced at higher pH than 7.8, and the positive error of the measured value is increased. However, there is no significant difference in the suppression effect of RF interference reaction by sulfite at pH 7.4 or lower.
また、表4より、正常検体では亜硫酸塩による干渉反応の抑制に対するpHの影響は、ほとんど見られない。これに対し、干渉物質が存在する異常検体では、pH7.8以上では亜硫酸塩の干渉反応の抑制効果が顕著に低下し測定値が高値化したが、pH6.4および6.8での測定値の変動は小さく、効果的に干渉反応が抑制されていることがわかる。 Further, from Table 4, almost no influence of pH on suppression of interference reaction by sulfite is observed in normal specimens. In contrast, in the case of an abnormal specimen in which an interfering substance is present, the suppression effect of the sulfite interference reaction was remarkably reduced and the measured value increased at pH 7.8 or higher, but the measured values at pH 6.4 and 6.8 were measured. It can be seen that the fluctuations in are small and the interference reaction is effectively suppressed.
実施例3 亜硫酸塩の干渉反応の抑制に対するpHの影響(詳細評価)
亜硫酸ナトリウムを250mMとして、干渉物質の干渉反応の抑制に対するpHの影響をさらに詳細に評価した。また、亜硫酸塩の酸化を促進する条件(試薬容器に半分充填し4℃で3週間振とう)で保存して安定性を評価した。
Example 3 Effect of pH on inhibition of interference reaction of sulfite (detailed evaluation)
Sodium sulfite was set to 250 mM, and the influence of pH on the suppression of the interference reaction of the interference substance was evaluated in more detail. Further, the stability was evaluated by storage under conditions that promote the oxidation of sulfite (half-filled reagent container and shaken at 4 ° C. for 3 weeks).
(1)試薬
第1試薬:150mM NaCl、0.1% NaN3、0.1% ポリオキシエチレンポリオキシプロピレンセチルエーテル、250mM 亜硫酸ナトリウムを含む50mM PIPES緩衝液(pH5.6、6.0、6.2、6.4、6.6、6.7、6.8または7.0)または50mM HEPES緩衝液(pH7.4)を調製した。また、調製した第1試薬を試薬容器に半分充填し、4℃で3週間振とうして亜硫酸塩の空気中の酸素による酸化を促進させた。
第2試薬:実施例1と同様である。
(2)測定試料
実施例1と同様にRF試料を調製した。
(3)評価方法
実施例1と同様に試料を測定した。調製直後の結果を表5に、亜硫酸塩の酸化を促進させた場合の結果を表6に示す。
(1) Reagent
First reagent: 50 mM PIPES buffer (pH 5.6, 6.0, 6.2, 6 containing 150 mM NaCl, 0.1% NaN 3 , 0.1% polyoxyethylene polyoxypropylene cetyl ether, 250 mM sodium sulfite .4, 6.6, 6.7, 6.8 or 7.0) or 50 mM HEPES buffer (pH 7.4) was prepared. The prepared first reagent was half filled in a reagent container and shaken at 4 ° C. for 3 weeks to promote oxidation of sulfite by oxygen in the air.
Second reagent: The same as in Example 1.
(2) Measurement sample An RF sample was prepared in the same manner as in Example 1.
(3) Evaluation method A sample was measured in the same manner as in Example 1. The results immediately after the preparation are shown in Table 5, and the results when the oxidation of sulfite is promoted are shown in Table 6.
表5から明らかなように、pH7.4の場合は、高濃度のRF(1000IU/mL)の干渉反応の抑制効果が不十分であるのに対し、pHが7.0以下の場合はRFの干渉反応の抑制効果に対するpHによる差異はなく、高濃度のRFに対しても高い抑制効果を持つことがわかった。 As can be seen from Table 5, when the pH is 7.4, the interference suppression effect of high concentration RF (1000 IU / mL) is insufficient, whereas when the pH is 7.0 or less, the RF It was found that there was no difference in pH with respect to the inhibitory effect of the interference reaction, and the inhibitory effect was high even for high concentrations of RF.
また、表5および表6より、pHが7.4の場合には、亜硫酸塩の酸化による干渉反応の抑制効果の低下が認められるのに対し、pHが7.0以下の場合は、RF干渉反応の抑制効果に対する亜硫酸塩の酸化の影響は認められず、亜硫酸塩を含有する試薬の安定性が向上することがわかった。前記結果および本結果から、亜硫酸塩を含有する免疫学的測定試薬または前処理試薬のpHは7.0以下が好ましく、pH5.6からpH7.0の範囲がより好ましい。 Further, from Table 5 and Table 6, when pH is 7.4, a decrease in the effect of suppressing interference reaction due to oxidation of sulfite is observed, whereas when pH is 7.0 or less, RF interference is observed. The influence of sulfite oxidation on the reaction inhibitory effect was not observed, and it was found that the stability of the reagent containing sulfite was improved. From the above results and the present results, the pH of the immunoassay reagent or pretreatment reagent containing sulfite is preferably 7.0 or less, and more preferably in the range of pH 5.6 to pH 7.0.
以上のように、本発明によれば、測定する試料中に異好性抗体やリウマトイド因子等の干渉物質が高濃度に含まれる場合であっても、これらによる干渉作用を長期間十分に抑制することができ、測定対象物を正確に測定ができる安定性の高い免疫学的測定方法および免疫学的測定試薬の提供が可能となる。 As described above, according to the present invention, even when a sample to be measured contains a high concentration of interfering substances such as heterophilic antibodies and rheumatoid factors, the interference action due to these is sufficiently suppressed for a long period of time. Therefore, it is possible to provide a highly stable immunoassay method and immunoassay reagent that can accurately measure a measurement object.
Claims (12)
An immunoassay comprising the immunological measurement reagent according to any one of claims 7 to 11 and an antibody or antigen that reacts with the measurement object, or an antibody or antigen that reacts with the measurement object or a carrier carrying the antigen. Reagent kit.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016205039A JP6857939B2 (en) | 2016-10-19 | 2016-10-19 | Immunological measurement method and measurement reagent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016205039A JP6857939B2 (en) | 2016-10-19 | 2016-10-19 | Immunological measurement method and measurement reagent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018066636A true JP2018066636A (en) | 2018-04-26 |
JP6857939B2 JP6857939B2 (en) | 2021-04-14 |
Family
ID=62086058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016205039A Active JP6857939B2 (en) | 2016-10-19 | 2016-10-19 | Immunological measurement method and measurement reagent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6857939B2 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61264262A (en) * | 1985-05-10 | 1986-11-22 | ベーリングヴェルケ・アクチェンゲゼルシャフト | Improved one-step heterogeneous assay |
JPH08146000A (en) * | 1994-11-17 | 1996-06-07 | Sekisui Chem Co Ltd | Immunity measuring method |
JP2000258420A (en) * | 1999-03-05 | 2000-09-22 | Azwell Inc | Stabilizing method of human-hemoglobin in solution and stabilizing solution |
JP2001074739A (en) * | 1999-09-06 | 2001-03-23 | Eiken Chem Co Ltd | Immunoassay, method for eliminating immunoreactive interference substance, and reagent for measuring it |
JP2009174871A (en) * | 2008-01-21 | 2009-08-06 | Fujifilm Corp | Immunological detection method |
WO2011001999A1 (en) * | 2009-06-30 | 2011-01-06 | 積水メディカル株式会社 | Immunological measurement reagent for use in measurement of kl-6 |
-
2016
- 2016-10-19 JP JP2016205039A patent/JP6857939B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61264262A (en) * | 1985-05-10 | 1986-11-22 | ベーリングヴェルケ・アクチェンゲゼルシャフト | Improved one-step heterogeneous assay |
JPH08146000A (en) * | 1994-11-17 | 1996-06-07 | Sekisui Chem Co Ltd | Immunity measuring method |
JP2000258420A (en) * | 1999-03-05 | 2000-09-22 | Azwell Inc | Stabilizing method of human-hemoglobin in solution and stabilizing solution |
JP2001074739A (en) * | 1999-09-06 | 2001-03-23 | Eiken Chem Co Ltd | Immunoassay, method for eliminating immunoreactive interference substance, and reagent for measuring it |
JP2009174871A (en) * | 2008-01-21 | 2009-08-06 | Fujifilm Corp | Immunological detection method |
WO2011001999A1 (en) * | 2009-06-30 | 2011-01-06 | 積水メディカル株式会社 | Immunological measurement reagent for use in measurement of kl-6 |
Also Published As
Publication number | Publication date |
---|---|
JP6857939B2 (en) | 2021-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090286330A1 (en) | Immunoassay using insoluble carrier particles and reagent therefor | |
JP4086266B2 (en) | Immunoassay method | |
JP4657328B2 (en) | Methods for removing immune reaction interfering substances | |
US9075049B2 (en) | Immunoassay method and reagent therefor | |
JP6857939B2 (en) | Immunological measurement method and measurement reagent | |
JP2004325414A (en) | Method and kit for measuring immunity | |
US20030143758A1 (en) | Insoluble carrier particle nephelometric immunoassay reagent | |
JP2010014586A (en) | Measurement method and measurement reagent kit of hemoglobin inside excrement specimen | |
WO2018074467A1 (en) | Immunoassay method and assay reagent | |
JP4278123B2 (en) | Immunological measurement method, immune reaction interfering substance removal method and measurement reagent | |
JP3220546B2 (en) | Method for measuring antigen or antibody in the presence of immune complex | |
JP2001255325A (en) | Immunoassay and reagent | |
JP6931673B2 (en) | Immunoassay methods and reagents | |
JP2684069B2 (en) | Method for measuring immunologically active substance and reagent therefor | |
WO2017090103A1 (en) | Immunoassay method and reagent kit | |
JP4556605B2 (en) | Target substance measurement method and reagent | |
WO2024038863A1 (en) | Immunoassay method and reagent | |
JP3041382B2 (en) | Immunoassay | |
JP2003028875A (en) | Nonspecific reaction suppressing immunoassay method | |
JP2004117068A (en) | Immunoassay reagent and immunoassay method | |
JP3246978B2 (en) | Method for producing reagent for measuring antigen or antibody | |
JP2005049264A (en) | Measuring method and measuring reagent of target material | |
JPH10311830A (en) | Immunoassay reagent and immunoassay | |
JP2000329764A (en) | Immunoassay and reagent | |
JPH10253629A (en) | Production of immunoassay reagent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191001 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200721 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200817 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201005 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201214 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210322 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210322 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6857939 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |